Company news
Pyxis Oncology, Inc. (NASDAQ:PYXS) news
Pyxis Oncology, Inc. news releases on 6ix. Latest, Sep 27, 2023: Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society…
Press releases — page 2
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
September 26, 2023
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
August 30, 2023
Pyxis Oncology Successfully Completes Acquisition of Apexigen
August 22, 2023
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
August 10, 2023
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
July 31, 2023
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
May 29, 2023
Pyxis Oncology to Acquire Apexigen
May 23, 2023
Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update
May 10, 2023
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
March 21, 2023
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
March 15, 2023
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
February 12, 2023
Pyxis Oncology Announces FDA Clearance of Two IND Applications
November 30, 2022
Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update
October 31, 2022
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update
August 14, 2022
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
June 27, 2022
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
May 18, 2022
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
May 12, 2022
Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference
April 26, 2022
Pyxis Oncology Announces Leadership Changes
April 12, 2022
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 7, 2022
Pyxis Oncology Provides Corporate and Financial Update
March 28, 2022
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
March 28, 2022
Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
March 21, 2022
Pyxis to be Added to Russell 2000® Index
December 14, 2021
Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer
December 8, 2021
Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
December 5, 2021
Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update
November 14, 2021
Pyxis Oncology to Present at the Jefferies London Healthcare Conference
November 9, 2021
Pyxis Announces Pricing of Upsized Initial Public Offering
October 6, 2021